{
  "denotations": [
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 105,
        "end": 140
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 158,
        "end": 167
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 196,
        "end": 223
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 196,
        "end": 205
      }
    },
    {
      "id": "T7",
      "obj": "Disease",
      "span": {
        "begin": 277,
        "end": 304
      }
    },
    {
      "id": "T8",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 277,
        "end": 286
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 80,
        "end": 93
      }
    },
    {
      "id": "T12",
      "obj": "Chemical",
      "span": {
        "begin": 105,
        "end": 111
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "17636396_11",
  "text": "CONCLUSIONS : Current evidence supports the conclusion that the benefit of both anthracycline -based and taxane -based adjuvant chemotherapy is associated on HER2 /neu status , with patients with HER2 /neu -positive cancers benefiting more from these therapies than those with HER2 /neu -negative cancers ."
}
